An oral small molecule drug may reduce gastrointestinal adverse events for adults using a GLP-1-based obesity drug, according ...
Geneva, Switzerland, August 27, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, ...
During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...
A new study published in Proceedings of the National Academy of Science (PNAS), reveals a causal link between dopamine and the reward responses in humans when listening to music. The study was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback